{"name":"Novocure","slug":"novocure","ticker":"NVCR","exchange":"NASDAQ","domain":"novocure.com","description":"NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.","hq":"Root, Switzerland","founded":0,"employees":"1605","ceo":"Asaf Danziger","sector":"Oncology Devices","stockPrice":11.05,"stockChange":0.7,"stockChangePercent":6.76,"marketCap":"$1.3B","metrics":{"revenue":655353000,"revenueGrowth":8.1,"grossMargin":74.8,"rdSpend":224544000,"netIncome":-136227000,"cash":447673984,"dividendYield":0,"peRatio":-9.5,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Optune patent cliff ($0.0B at risk)","drug":"Optune","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Optune Lua patent cliff ($0.0B at risk)","drug":"Optune Lua","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Optune AURA patent cliff ($0.0B at risk)","drug":"Optune AURA","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Immune checkpoint inhibitors or docetaxel","genericName":"Immune checkpoint inhibitors or docetaxel","slug":"immune-checkpoint-inhibitors-or-docetaxel","indication":"Non-small cell lung cancer (Phase 3 trials)","status":"phase_3"}]}],"pipeline":[{"name":"Immune checkpoint inhibitors or docetaxel","genericName":"Immune checkpoint inhibitors or docetaxel","slug":"immune-checkpoint-inhibitors-or-docetaxel","phase":"phase_3","mechanism":"This is a combination approach using immune checkpoint inhibitors to enhance anti-tumor immunity and/or docetaxel chemotherapy to directly kill cancer cells.","indications":["Non-small cell lung cancer (Phase 3 trials)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Novocure Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Novocure reported fourth quarter and full year 2023 financial results, with revenue of $243.8 million and $944.8 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Novocure Announces Collaboration with Bristol Myers Squibb to Develop Tumor Treating Fields for Solid Tumors","summary":"Novocure announced a collaboration with Bristol Myers Squibb to develop Tumor Treating Fields for solid tumors.","drugName":"","sentiment":"positive"},{"date":"2023-09-18","type":"regulatory","headline":"Novocure Receives FDA Approval for Optune AURA for Newly Diagnosed Glioblastoma","summary":"Novocure received FDA approval for Optune AURA for newly diagnosed glioblastoma.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5QZm5DV0tsU0FCM3RYcUhBOUwyNkN0VVVVTGJla0VvaFdCR3NYRFhfMk9reU5zQVUtckg4dnZrTG5oUG1McmdXa3lYSW9ZTzE2b1pv?oc=5","date":"2026-02-28","type":"earnings","source":"Intellectia AI","summary":"NVCR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI","headline":"NVCR Stock News Today | Earnings, Events & Price Alerts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQbm9kYWVGVERCdmNvNUJ4WmpYZmRTSk03c3dRanlKUVQ3VVhTUHNWRGxpNi1rNzRobFFrdHJQendMZjdSQUwzbk1uSEpTVUJGWnpWYzhpMmpWU1pYVTBXTjRUOWl0Q0pTZFVOaVZzaFdZNU1aMHNPMkNKeDQ1dUNsMFNXYkNSNlZJdEw0eA?oc=5","date":"2026-02-19","type":"earnings","source":"Yahoo Finance","summary":"Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance","headline":"Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxORjlmS25WZXJ3UnNyMG5Kc1hkS0JNTERVRWtUWWxrVmNkRGtfbHBJUnVLM3ZzTjNsYnp5cG1CdlJnd1VsUFZFNVh5cVpaUEdkYUlibEdTeUNQNmZQYXB1RkszZDhUd3djNUdPd0Z5ZzlxZjNhMWxqMGRVbjdINzZSaWNHazhEQVBWRGNsRVNiSFlwZlViVmFCM3BSem9MeTFxcVU5bkxRY0szYXhoZ1cySkdsZUlwUGhtV05PS3hlbXo1bUVBTVBHTjNSWk9IZXc?oc=5","date":"2026-02-13","type":"regulatory","source":"RTTNews","summary":"Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace - RTTNews","headline":"Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQVzREWEJvRzBGZ2NZend1SjBnN2hpbzJuaWpJN0pUbU05b29rMl9DY1JyYTFySnVFcWVrV3I3SUJoNThVNWJQSGFYX0NWNEtUWGxoRjRNSFdIeVlyWEh4QjhTcHVvOW8zc19RdTRzQzdNNGZFZ2tfTmFPNUktZkR0MzBINWpOWHpFU25GLVJTdVd5MkUwX1BDankxajRaYTdBRzhRUDNOaHpTRkdtSUg1bHE2QQ?oc=5","date":"2026-02-11","type":"regulatory","source":"WSJ","summary":"Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar - WSJ","headline":"Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPOE12ZV9XOXRDcmlESHhQUzAyVHRKbWtFREZwQVhyMm9iODAySFktZ1RaRXFGOV9HOTh4VW1Ta18tYW1qeGNYblh3VFJNQTgtX1BrYndBNWFaRkRfVkZFQzNieHBUR1JFcTVWOUcteHFqMm9uWFdtN0NRd3BKa1RFWTh0WXJ0TDYzQzVqTzF3ZmdfakVVU2wxcA?oc=5","date":"2026-02-06","type":"pipeline","source":"Seeking Alpha","summary":"Why NovoCure Is No Longer A Clear Sell At These Lows (NASDAQ:NVCR) - Seeking Alpha","headline":"Why NovoCure Is No Longer A Clear Sell At These Lows (NASDAQ:NVCR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeVdhRVlLelQxRjlZRHR6T1dRQ3VLSXg5VzV3Vm1rMFU0RzRwUzEzR2dQaEJ6VGZyTVR5SVF5OHRMQkdqN0hKaFlvMy1adER3M1FjYmpjMU1lNFZXU2ZSSXB5cXdRN1h0eUxEM0hmY2Z4ek43dEI3X0QzSzV4NjVvNk1VS3NUQUJRQmowQTZvQlYyVzUwZ2FHQ3VHeHRPSTNYWl9fZmR2TVI?oc=5","date":"2026-01-02","type":"deal","source":"Seeking Alpha","summary":"NovoCure: 2026 Pipeline Outlook Make This Stock A Speculative Buy (NASDAQ:NVCR) - Seeking Alpha","headline":"NovoCure: 2026 Pipeline Outlook Make This Stock A Speculative Buy (NASDAQ:NVCR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQS3VMdXNWN241UWk1ZU5YQTVHemJLVl94TlNzRTYzWDN1cUl0Mk5xRFU0dFU1U2FfTXphRExBYjRVRXp6OTdpeU9VT3ducTRXbkhjX2tycEpHSUVhWWJYRVJRWFVuY3MwMVZqVU15VG92UXBkV2o1MkE3SEVTVUx4RG1LTzhrbGdlM3I1UXVEOWFiam5md0ow?oc=5","date":"2025-11-12","type":"pipeline","source":"The Motley Fool","summary":"2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon - The Motley Fool","headline":"2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPaUZmaWtXV2l6aXlpWUZ3QzhKeEg1UmI2d3BVT0w3YlpJS204OVhPSEx1WEtROEZqQWM4ZHhfYUw5M0JlZ0Z5V21CczFpamp4ZExXaTJPcEVNaFNBWUdZUjZtMVFFWmYyS0pFS1A2ZlJBMTlUbGFWb2Z4TXQ2Q0JGVnlNQnZ5aGZGd21kcEE4Ykl2UmdiZzMxemcwbWJKa2hP?oc=5","date":"2025-04-22","type":"pipeline","source":"Mugglehead Magazine","summary":"Novocure sees 6% spike from EU nod for electric lung cancer therapy gadget - Mugglehead Magazine","headline":"Novocure sees 6% spike from EU nod for electric lung cancer therapy gadget","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOVGV4MzFIa3E1VnZEVWFLUk9YcVhWYmFzamdicFMxQmtkV0lWdTRkM1dFaWdXS0ZjdGdhTDRSX2ROWmRsOTJVdXNDbkQ2amp2cWpwTlk2NzRsc05zaE5WTjl2WV8xc3ZiamdjODFoQVQwdzVQbllRUHhuNmdTUEJGdHBPLVpicDZ5ZjJkdk42RlZGWWRyVXBrOEduOFhwX1lnc0F1UVp5WDRRMjhZOFB6UUJ3Mi0tYzNUMDExN3pId2xHcDVHQ3B4bm5n?oc=5","date":"2025-01-22","type":"earnings","source":"Business Wire","summary":"Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland - Business Wire","headline":"Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPc2N2cHZQUEU5MlkxNDcxcWRNajRhd3VYS09vUnY1Z3VkclFnejV5ZjBTOE9ERDZPSjVzOFRJLTNWWUFFUkRSUm0wLWhSNmlUblFUVThNcmNYVW9pd0Nfa2xSb2QzSktqYVhQdlFNdnprVnhZUE1NRkpqZ01ET1dMbGVyb1lrR213cllOLUdJaVhfaTFhVXFKS2JhdlBTWGtvZjJHVG1naw?oc=5","date":"2024-12-02","type":"regulatory","source":"The Pharma Letter","summary":"Novocure close to regulatory filing on results from Phase III PANOVA-3 trial - The Pharma Letter","headline":"Novocure close to regulatory filing on results from Phase III PANOVA-3 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1IcFJjQVZqTENjTnVIb2l5dnVZd3Jac3Nzb2IyT3FSSFpTY0U2Ym9uc2dsbC00SGFiNkVRa3p3cjhIZGNJMkhtUUs3Y1l5Rk1XUURKUFhudW1pc1dmTDNlaXhRSTBBV0NYVmd6S0c5Y3YybkE?oc=5","date":"2024-10-16","type":"regulatory","source":"The Pharma Letter","summary":"FDA approves Novocure’s Optune Lua - The Pharma Letter","headline":"FDA approves Novocure’s Optune Lua","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE40Wklqd2VRdkhGb0lNbTVCYkV3SzNOUEpYNU5vdW9jSkdfS25aQVZXcHE0WHlSNGhuRTlCd2ZkUUlES3VfNTZGX1M1a2VsaGlq?oc=5","date":"2024-01-18","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Optune","drugSlug":"tumor-treating-fields","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"Optune Lua","drugSlug":"tumor-treating-fields","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"Optune AURA","drugSlug":"tumor-treating-fields","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Stryker","Medtronic","Varian Medical Systems"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar","revenue":655353000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":655353000,"period":"2025-12-31"},{"value":605220000,"period":"2024-12-31"},{"value":605220000,"period":"2024-12-31"},{"value":509338000,"period":"2023-12-31"},{"value":509338000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":224544000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-136227000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":804326000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":11.05,"previousClose":10.35,"fiftyTwoWeekHigh":20.06,"fiftyTwoWeekLow":9.82,"fiftyTwoWeekRange":"9.82 - 20.06","fiftyDayAverage":11.98,"twoHundredDayAverage":13.04,"beta":0.82,"enterpriseValue":978451008,"forwardPE":-9.5,"priceToBook":3.65,"priceToSales":1.92,"enterpriseToRevenue":1.49,"enterpriseToEbitda":-7.24,"pegRatio":0,"ebitda":-135159008,"ebitdaMargin":-20.6,"freeCashflow":-37975376,"operatingCashflow":-49031000,"totalDebt":248352992,"debtToEquity":72.9,"currentRatio":2.9,"returnOnAssets":-9.1,"returnOnEquity":-38.9,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":7,"targetMeanPrice":25.07,"targetHighPrice":49,"targetLowPrice":13.5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":9.5,"institutionHeldPercent":86,"sharesOutstanding":113794396,"floatShares":94631420,"sharesShort":8518264,"shortRatio":3.86,"shortPercentOfFloat":7.5,"epsTrailing":-1.2,"epsForward":-1.17,"revenuePerShare":5.88,"bookValue":3.03,"officers":[{"age":63,"name":"Mr. William F. Doyle","title":"Executive Chairman"},{"age":null,"name":"Mr. Frank  Leonard","title":"Chief Executive Officer"},{"age":48,"name":"Mr. Barak  Ben-Arye","title":"General Counsel"},{"age":46,"name":"Dr. Uri  Weinberg M.D., Ph.D.","title":"Chief Innovation Officer & Chief Medical Officer"},{"age":51,"name":"Mr. Christoph  Brackmann","title":"Chief Financial Officer"},{"age":55,"name":"Mr. Mukund  Paravasthu","title":"Chief Operating Officer"},{"age":null,"name":"Mr. Adam  Daney","title":"Head of Investor Relations"},{"age":56,"name":"Mr. Michael  Puri","title":"Chief Human Resources Officer"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.novocure.com","phone":""}}